News | March 02, 2024
Cipla incorporates JV company in USA
Cipla completes transfer of Generics Business Undertaking
Cipla completes transfer of Generics Business Undertaking
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
BHL will undertake the development and supply of these molecules
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
MoU to serve as the establishment of an Academic Collaboration in Ayurveda and Thai Traditional Medicine
Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon
Subscribe To Our Newsletter & Stay Updated
